The Broken Heart Study II (BHS-II)

Last updated: April 23, 2025
Sponsor: The Miriam Hospital
Overall Status: Active - Not Recruiting

Phase

N/A

Condition

Cardiomyopathy

Congestive Heart Failure

Heart Disease

Treatment

Stress reactivity test

Clinical Study ID

NCT04325321
R01HL149672
R01HL149672
  • Ages > 18
  • All Genders

Study Summary

The goals of this study are as follows:

  1. To rigorously establish and characterize heterogeneity in the pathophysiology of Takotsubo Syndrome (TS).

  2. To rigorously test the contribution of TS triggering events and mental stress responsiveness to 1-year prognosis after TS event.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >=18

  • A new diagnosis of takotsubo syndrome fulfilling Mayo Clinic criteria

  • Ability to understand and speak English

Exclusion

Exclusion Criteria:

  • Inability or unwillingness to give informed consent

  • Severe cognitive impairment

  • Uncontrolled hypertension

  • Acute psychosis

  • High suicidal risk

  • Pregnancy

  • Poor echocardiographic window

  • Conditions that would interfere with adherence to study requirements (e.g., ongoingalcohol or substance abuse)

  • If the participant is clinically unstable

Study Design

Total Participants: 66
Treatment Group(s): 1
Primary Treatment: Stress reactivity test
Phase:
Study Start date:
September 02, 2020
Estimated Completion Date:
February 28, 2026

Study Description

Newly admitted patients with a validated diagnosis of Takotsubo Syndrome (TS; n=106) will be enrolled from 3 large medical centers in the Providence, Rhode Island area. Between 2 and 4 weeks after discharge, clinically stable patients will undergo an in-person comprehensive interview to identify the events proximal to the onset of TS symptoms, complete a battery of psychosocial questionnaires and undergo a validated laboratory stress protocol. Baseline and reactive changes in measures of autonomic nervous system activity (epinephrine and norepinephrine - primary outcome), and in the secondary outcomes of cardiac vagal control and left ventricular function (ejection fraction; regional and global longitudinal strain assessed with speckle tracking echocardiography) will be assessed. Echocardiographic evaluations will be repeated 12 months thereafter together with information on major adverse cerebrovascular events.

Connect with a study center

  • The Miriam Hospital

    Providence, Rhode Island 02906
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.